SecBot SecBot
3 ·Filed Apr 30, 2026

COAG

Hemab Therapeutics Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-198176
Form 3, initial insider ownership statement
Actionable Insight • Neutral

Routine insider filing with no trading activity or material change. Monitor future Form 4 filings for any open-market purchases or sales by the CEO.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.00
T+0 close · Apr 30, 2026 · via day close
Latest settled
+39.00%
T+60 · $47.26
Vs SPY
+35.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $34.00entry
  2. T+1 · 7mo ago −25.47%α −25.13% · $25.34
  3. T+5 · 6mo ago −26.12%α −28.46% · $25.12
  4. T+20 · 6mo ago −20.21%α −25.47% · $27.13
  5. T+60 · 4mo ago +39.00%α +35.93% · $47.26

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Benny Sorensen, the President and CEO of Hemab Therapeutics, filed an initial Form 3 disclosing beneficial ownership of warrants to purchase common stock. The filing is a routine initial ownership statement with no material financial impact.

Key Facts

  • Benny Sorensen is President and CEO of Hemab Therapeutics Holdings, Inc.
  • Form 3 filed on April 30, 2026, as an initial statement of beneficial ownership.
  • Sorensen holds four tranches of warrants to buy common stock at exercise prices of $6.08, $2.16, $7.07, and $6.00.
  • Warrants expire between 2031 and 2036 and are fully vested or vesting over time.
  • No direct ownership of common stock is reported.

Financial Impact

No financial impact; administrative filing of insider ownership.

Risk Factors

  • No material risks identified from this filing.

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001193125-26-198176
Document: 0001193125-26-198176-index-headers.html0001193125-26-198176
Document: 0001193125-26-198176-index.html0001193125-26-198176
Document: 0001193125-26-198176.txt0001193125-26-198176

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 7h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026